Requests that the FDA Reverse its decision to classify desiccated thyroid extract (DTE) as a biological product under the PHS Act; Clarify that the August 6, 2025 Notice to Industry; Affirm that natural thyroid products should, if approved, proceed through the drug approval pathway under section 505 of the FD&C Act; regarding the classification and regulation of DTE products